Cargando…
Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial
OBJECTIVE: To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549283/ https://www.ncbi.nlm.nih.gov/pubmed/31171523 http://dx.doi.org/10.1136/bmj.l2211 |
_version_ | 1783423973261836288 |
---|---|
author | Wang, Yilong Chen, Weiqi Lin, Yi Meng, Xia Chen, Guohua Wang, Zhimin Wu, Jialing Wang, Dali Li, Jianhua Cao, Yibin Xu, Yuming Zhang, Guohua Li, Xiaobo Pan, Yuesong Li, Hao Zhao, Xingquan Liu, Liping Lin, Jinxi Dong, Kehui Jing, Jing Johnston, S Claiborne Wang, David Wang, Yongjun |
author_facet | Wang, Yilong Chen, Weiqi Lin, Yi Meng, Xia Chen, Guohua Wang, Zhimin Wu, Jialing Wang, Dali Li, Jianhua Cao, Yibin Xu, Yuming Zhang, Guohua Li, Xiaobo Pan, Yuesong Li, Hao Zhao, Xingquan Liu, Liping Lin, Jinxi Dong, Kehui Jing, Jing Johnston, S Claiborne Wang, David Wang, Yongjun |
author_sort | Wang, Yilong |
collection | PubMed |
description | OBJECTIVE: To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function allele and patients with large artery atherosclerosis. DESIGN: Open label, blinded endpoint, randomised controlled phase II trial. SETTING: Prospective studies conducted at 26 centres in China, August 2015 to March 2017. PARTICIPANTS: 675 patients with acute minor stroke or transient ischaemic attack. INTERVENTION: Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300 mg loading dose, 75 mg daily thereafter) on a background of aspirin (100 mg daily for the first 21 days) within 24 hours of symptom onset. MAIN OUTCOME MEASURES: Primary outcome was the proportion of patients with high platelet reactivity at 90 days. High platelet reactivity was defined as P2Y12 reaction units of more than 208. Secondary outcomes included high platelet reactivity at 90 days (7 days either way) in patients carrying genetic variants that would affect clopidogrel metabolism, and any stroke (ischaemic or haemorrhagic) recurrence at 90 days (7 days either way), six months, and one year. RESULTS: At 90 days, high platelet reactivity occurred in 35 (12.5%) of 280 patients in the ticagrelor/aspirin group and 86 (29.7%) of 290 patients in the clopidogrel/aspirin group (risk ratio 0.40; 95% confidence interval 0.28 to 0.56; P<0.001), and in 10.8% versus 35.4% (0.31; 0.18 to 0.49; P<0.001) of patients carrying CYP2C19 loss-of-function alleles. Stroke occurred in 21 (6.3%) of 336 patients in the ticagrelor/aspirin group and 30 (8.8%) of 339 patients in the clopidogrel/aspirin group (hazard ratio 0.70; 95% confidence interval 0.40 to 1.22; P=0.20). Patients with large artery atherosclerosis in the ticagrelor/aspirin group had a lower stroke recurrence at 90 days than those in the clopidogrel/aspirin group (6.0% v 13.1%; hazard ratio 0.45, 95% confidence interval 0.20 to 0.98; P=0.04). No difference was seen in the rates of major or minor haemorrhagic events between the ticagrelor/aspirin and clopidogrel/aspirin groups (4.8% v 3.5%; P=0.42). CONCLUSION: Patients with minor stroke or transient ischaemic attack who are treated with ticagrelor plus aspirin have a lower proportion of high platelet reactivity than those who are treated with clopidogrel plus aspirin, particularly for those who are carriers of the CYP2C19 loss-of-function allele. The results of this study should be evaluated further in large scale, phase III trials and in different populations. TRIAL REGISTRATION: Clinicaltrials.gov NCT02506140. |
format | Online Article Text |
id | pubmed-6549283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65492832019-06-19 Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial Wang, Yilong Chen, Weiqi Lin, Yi Meng, Xia Chen, Guohua Wang, Zhimin Wu, Jialing Wang, Dali Li, Jianhua Cao, Yibin Xu, Yuming Zhang, Guohua Li, Xiaobo Pan, Yuesong Li, Hao Zhao, Xingquan Liu, Liping Lin, Jinxi Dong, Kehui Jing, Jing Johnston, S Claiborne Wang, David Wang, Yongjun BMJ Research OBJECTIVE: To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function allele and patients with large artery atherosclerosis. DESIGN: Open label, blinded endpoint, randomised controlled phase II trial. SETTING: Prospective studies conducted at 26 centres in China, August 2015 to March 2017. PARTICIPANTS: 675 patients with acute minor stroke or transient ischaemic attack. INTERVENTION: Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300 mg loading dose, 75 mg daily thereafter) on a background of aspirin (100 mg daily for the first 21 days) within 24 hours of symptom onset. MAIN OUTCOME MEASURES: Primary outcome was the proportion of patients with high platelet reactivity at 90 days. High platelet reactivity was defined as P2Y12 reaction units of more than 208. Secondary outcomes included high platelet reactivity at 90 days (7 days either way) in patients carrying genetic variants that would affect clopidogrel metabolism, and any stroke (ischaemic or haemorrhagic) recurrence at 90 days (7 days either way), six months, and one year. RESULTS: At 90 days, high platelet reactivity occurred in 35 (12.5%) of 280 patients in the ticagrelor/aspirin group and 86 (29.7%) of 290 patients in the clopidogrel/aspirin group (risk ratio 0.40; 95% confidence interval 0.28 to 0.56; P<0.001), and in 10.8% versus 35.4% (0.31; 0.18 to 0.49; P<0.001) of patients carrying CYP2C19 loss-of-function alleles. Stroke occurred in 21 (6.3%) of 336 patients in the ticagrelor/aspirin group and 30 (8.8%) of 339 patients in the clopidogrel/aspirin group (hazard ratio 0.70; 95% confidence interval 0.40 to 1.22; P=0.20). Patients with large artery atherosclerosis in the ticagrelor/aspirin group had a lower stroke recurrence at 90 days than those in the clopidogrel/aspirin group (6.0% v 13.1%; hazard ratio 0.45, 95% confidence interval 0.20 to 0.98; P=0.04). No difference was seen in the rates of major or minor haemorrhagic events between the ticagrelor/aspirin and clopidogrel/aspirin groups (4.8% v 3.5%; P=0.42). CONCLUSION: Patients with minor stroke or transient ischaemic attack who are treated with ticagrelor plus aspirin have a lower proportion of high platelet reactivity than those who are treated with clopidogrel plus aspirin, particularly for those who are carriers of the CYP2C19 loss-of-function allele. The results of this study should be evaluated further in large scale, phase III trials and in different populations. TRIAL REGISTRATION: Clinicaltrials.gov NCT02506140. BMJ Publishing Group Ltd. 2019-06-05 /pmc/articles/PMC6549283/ /pubmed/31171523 http://dx.doi.org/10.1136/bmj.l2211 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Research Wang, Yilong Chen, Weiqi Lin, Yi Meng, Xia Chen, Guohua Wang, Zhimin Wu, Jialing Wang, Dali Li, Jianhua Cao, Yibin Xu, Yuming Zhang, Guohua Li, Xiaobo Pan, Yuesong Li, Hao Zhao, Xingquan Liu, Liping Lin, Jinxi Dong, Kehui Jing, Jing Johnston, S Claiborne Wang, David Wang, Yongjun Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial |
title | Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial |
title_full | Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial |
title_fullStr | Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial |
title_full_unstemmed | Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial |
title_short | Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial |
title_sort | ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase ii trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549283/ https://www.ncbi.nlm.nih.gov/pubmed/31171523 http://dx.doi.org/10.1136/bmj.l2211 |
work_keys_str_mv | AT wangyilong ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT chenweiqi ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT linyi ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT mengxia ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT chenguohua ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT wangzhimin ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT wujialing ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT wangdali ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT lijianhua ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT caoyibin ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT xuyuming ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT zhangguohua ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT lixiaobo ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT panyuesong ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT lihao ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT zhaoxingquan ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT liuliping ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT linjinxi ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT dongkehui ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT jingjing ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT johnstonsclaiborne ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT wangdavid ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial AT wangyongjun ticagrelorplusaspirinversusclopidogrelplusaspirinforplateletreactivityinpatientswithminorstrokeortransientischaemicattackopenlabelblindedendpointrandomisedcontrolledphaseiitrial |